Oliver Rosen
Chief Medical Officer Akamis Bio
Oliver is a seasoned physician-scientist committed to innovative drug development approaches reflecting all stakeholder perspectives including patients, health technology assessment bodies, and payers. He is passionate about successful translation from bench to bedside, dose optimization, and communication to all audiences. He has supported private financing rounds and 2 IPOs (Nasdaq, NYSE) and is dedicated to ensuring global patient access to medicines addressing unmet medical needs.
His academic career focused on the first applications of autologous stem-cell transplantations in patients with refractory autoimmune diseases and the systematic administration of prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in adults with hematological malignancies.
Oliver is engaged in oncology community activities to improve clinical drug development, facilitated by Friends of Cancer Research and the American Society of Clinical Oncology. He is also active in the Boston community and currently serves on the Board of Mentors of Community Servings.
Seminars
- Clinical and regulatory utility of first generation ctDNA assays
- The need for innovative endpoints and important advancements of ctDNA assays to serve as MRD assays
- An example of a potential pathway to establish ctDNA for MRD testing in a solid tumor indication
